Association of the apolipoprotein B/apolipoprotein A1 ratio with 90-day mortality after acute intracerebral hemorrhage: a single-center cohort study

Background and purpose Previous studies have linked lipid measures to hematoma expansion and outcomes after intracerebral hemorrhage (ICH), but prognostic evidence for the apolipoprotein B/apolipoprotein A1 (ApoB/ApoA1) ratio remains limited. We examined the associations of acute-phase ApoB/ApoA1 with 90-day mortality and poor functional outcome after primary ICH and evaluated its incremental prognostic information beyond the ICH score. Methods We conducted a single-center observational cohort study of adults with primary ICH who underwent baseline CT within 72 h after symptom onset. The primary outcome was 90-day all-cause mortality; the secondary outcome was poor functional outcome at 90 days. Logistic regression examined associations of ApoB/ApoA1 with outcomes in unadjusted and ICH score-adjusted models. Incremental value beyond the ICH score was assessed using discrimination, Brier score, calibration, and bootstrap internal validation. Results Among 470 included patients, 73 (15.5%) died and 190 (40.4%) had poor functional outcome at 90 days. Higher ApoB/ApoA1 was associated with lower 90-day mortality after adjustment for the ICH score (OR per 0.1-unit increase, 0.82; 95% CI, 0.71–0.96; p = 0.012), but not with poor functional outcome (OR, 0.97; 95% CI, 0.90–1.06; p = 0.531). Adding ApoB/ApoA1 to the ICH score yielded a limited increase in discrimination for 90-day mortality (ΔAUC, 0.027; bootstrap 95% CI, 0.008–0.057; likelihood-ratio p = 0.008), with little change in Brier score or calibration. No meaningful improvement was observed for poor functional outcome. Conclusion Higher acute-phase ApoB/ApoA1 was associated with lower 90-day mortality, but not poor functional outcome, after accounting for the ICH score. ApoB/ApoA1 provided limited incremental prognostic information for 90-day mortality beyond the ICH score. Clinical usefulness remains uncertain, and external validation is needed.

Authors

Institutions

Publication Details

Journal
Frontiers in Neurology
Published
2026-10-29
DOI
https://doi.org/10.3389/fneur.2026.1898784
Primary Topic
Intracerebral and Subarachnoid Hemorrhage Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association of the apolipoprotein B/apolipoprotein A1 ratio with 90-day mortality after acute intracerebral hemorrhage: a single-center cohort study

Wen‐Song Yang, Shuqiang Zhang, Yong-Bo Ma, Rui Feng et al.
3 links
Frontiers in Neurology
Intracerebral and Subarachnoid Hemorrhage Research
article

Association of the apolipoprotein B/apolipoprotein A1 ratio with 90-day mortality after acute intracerebral hemorrhage: a single-center cohort study

Wen‐Song Yang, Shuqiang Zhang, Yong-Bo Ma, Rui Feng, You-Dong Wei, Jun-Meng Huang, Chao-Yi Huang
article en

Abstract

Background and purpose Previous studies have linked lipid measures to hematoma expansion and outcomes after intracerebral hemorrhage (ICH), but prognostic evidence for the apolipoprotein B/apolipoprotein A1 (ApoB/ApoA1) ratio remains limited. We examined the associations of acute-phase ApoB/ApoA1 with 90-day mortality and poor functional outcome after primary ICH and evaluated its incremental prognostic information beyond the ICH score. Methods We conducted a single-center observational cohort study of adults with primary ICH who underwent baseline CT within 72 h after symptom onset. The primary outcome was 90-day all-cause mortality; the secondary outcome was poor functional outcome at 90 days. Logistic regression examined associations of ApoB/ApoA1 with outcomes in unadjusted and ICH score-adjusted models. Incremental value beyond the ICH score was assessed using discrimination, Brier score, calibration, and bootstrap internal validation. Results Among 470 included patients, 73 (15.5%) died and 190 (40.4%) had poor functional outcome at 90 days. Higher ApoB/ApoA1 was associated with lower 90-day mortality after adjustment for the ICH score (OR per 0.1-unit increase, 0.82; 95% CI, 0.71–0.96; p = 0.012), but not with poor functional outcome (OR, 0.97; 95% CI, 0.90–1.06; p = 0.531). Adding ApoB/ApoA1 to the ICH score yielded a limited increase in discrimination for 90-day mortality (ΔAUC, 0.027; bootstrap 95% CI, 0.008–0.057; likelihood-ratio p = 0.008), with little change in Brier score or calibration. No meaningful improvement was observed for poor functional outcome. Conclusion Higher acute-phase ApoB/ApoA1 was associated with lower 90-day mortality, but not poor functional outcome, after accounting for the ICH score. ApoB/ApoA1 provided limited incremental prognostic information for 90-day mortality beyond the ICH score. Clinical usefulness remains uncertain, and external validation is needed.

Frontiers in NeurologyVol. 17
Chongqing University (CN), Fuling Center Hospital of Chongqing (CN), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Chongqing Medical University (CN)
Good health and well-being
Openalex Percentile: Top 14%
Intracerebral and Subarachnoid Hemorrhage Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon